HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells.

Abstract
Histone deacetylase (HDAC) inhibitors (HDI) induce endoplasmic reticulum (ER) stress and apoptosis, while promoting autophagy, which promotes cancer cell survival when apoptosis is compromised. Here, we determined the in vitro and in vivo activity of the combination of the pan-HDI panobinostat and the autophagy inhibitor chloroquine against human estrogen/progesterone receptor and HER2 (triple)-negative breast cancer (TNBC) cells. Treatment of MB-231 and SUM159PT cells with panobinostat disrupted the hsp90/histone deacetylase 6/HSF1/p97 complex, resulting in the upregulation of hsp. This was accompanied by the induction of enhanced autophagic flux as evidenced by increased expression of LC3B-II and the degradation of the autophagic substrate p62. Treatment with panobinostat also induced the accumulation and colocalization of p62 with LC3B-II in cytosolic foci as evidenced by immunofluorescent confocal microscopy. Inhibition of panobinostat-induced autophagic flux by chloroquine markedly induced the accumulation of polyubiquitylated proteins and p62, caused synergistic cell death of MB-231 and SUM159PT cells, and inhibited mammosphere formation in MB-231 cells, compared with treatment with each agent alone. Finally, in mouse mammary fat pad xenografts of MB-231 cells, a tumor size-dependent induction of heat shock response, ER stress and autophagy were observed. Cotreatment with panobinostat and chloroquine resulted in reduced tumor burden and increased the survival of MB-231 breast cancer xenografts. Collectively, our findings show that cotreatment with an autophagy inhibitor and pan-HDI, for example, chloroquine and panobinostat results in accumulation of toxic polyubiquitylated proteins, exerts superior inhibitory effects on TNBC cell growth, and increases the survival of TNBC xenografts.
AuthorsRekha Rao, Ramesh Balusu, Warren Fiskus, Uma Mudunuru, Sreedhar Venkannagari, Lata Chauhan, Jacqueline E Smith, Stacey L Hembruff, Kyungsoo Ha, Peter Atadja, Kapil N Bhalla
JournalMolecular cancer therapeutics (Mol Cancer Ther) Vol. 11 Issue 4 Pg. 973-83 (Apr 2012) ISSN: 1538-8514 [Electronic] United States
PMID22367781 (Publication Type: Journal Article)
Copyright©2012 AACR.
Chemical References
  • HSP90 Heat-Shock Proteins
  • Histone Deacetylase Inhibitors
  • Hydroxamic Acids
  • Indoles
  • Chloroquine
  • Panobinostat
Topics
  • Animals
  • Antineoplastic Combined Chemotherapy Protocols (pharmacology)
  • Apoptosis
  • Autophagy
  • Breast Neoplasms (drug therapy, metabolism, pathology)
  • Cell Line, Tumor
  • Chloroquine (administration & dosage, pharmacology)
  • Drug Synergism
  • Female
  • HSP90 Heat-Shock Proteins (antagonists & inhibitors, metabolism)
  • Histone Deacetylase Inhibitors (administration & dosage, pharmacology)
  • Humans
  • Hydroxamic Acids (administration & dosage, pharmacology)
  • Indoles
  • Mice
  • Mice, Inbred NOD
  • Mice, SCID
  • Microscopy, Confocal
  • Panobinostat
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: